↓ Skip to main content

Cochrane Database of Systematic Reviews

Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants

Overview of attention for article published in Cochrane database of systematic reviews, July 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
246 Dimensions

Readers on

mendeley
185 Mendeley
connotea
1 Connotea
Title
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants
Published in
Cochrane database of systematic reviews, July 2010
DOI 10.1002/14651858.cd000174.pub2
Pubmed ID
Authors

Peter W Fowlie, Peter G Davis, William McGuire

Abstract

Persistent patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants. Prostaglandin synthetase inhibitors such as indomethacin promote PDA closure but also have potential side effects. The effect of the prophylactic use of indomethacin, where infants who may not have gone on to develop a symptomatic PDA would be exposed to indomethacin, warrants particular scrutiny. To determine the effect of prophylactic indomethacin on mortality and morbidity in preterm infants. The standard search strategy of the Cochrane Neonatal Review Group was used. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 5, 2010), MEDLINE, EMBASE and CINAHL (until April 2010), conference proceedings, and previous reviews. Randomised or quasi-randomised controlled trials that compared prophylactic indomethacin versus placebo or no drug in preterm infants. The standard methods of the Cochrane Neonatal Review Group were used, with separate evaluation of trial quality and data extraction by two review authors. Nineteen eligible trials in which 2872 infants participated were identified. Most participants were very low birth weight, but the largest single trial restricted participation to extremely low birth weight infants (N = 1202). The trials were generally of good quality.The incidence of symptomatic PDA [typical relative risk (RR) 0.44, 95% confidence interval (CI) 0.38 to 0.50] and PDA surgical ligation (typical RR 0.51, 95% CI 0.37,0.71) was significantly lower in treated infants. Prophylactic indomethacin also significantly reduced the incidence of severe intraventricular haemorrhage (typical RR 0.66, 95% CI 0.53 to 0.82). Meta-analyses found no evidence of an effect on mortality (typical RR 0.96, 95% CI 0.81 to 1.12) or on a composite of death or severe neurodevelopmental disability assessed at 18 to 36 months old (typical RR 1.02, 95% CI 0.90, 1.15). Prophylactic indomethacin has short-term benefits for preterm infants including a reduction in the incidence of symptomatic PDA, PDA surgical ligation, and severe intraventricular haemorrhage. However, there is no evidence of effect on mortality or neurodevelopment.

Mendeley readers

The data shown below were compiled from readership statistics for 185 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ethiopia 1 <1%
Brazil 1 <1%
South Africa 1 <1%
United Kingdom 1 <1%
United States 1 <1%
Unknown 180 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 26 14%
Student > Master 24 13%
Student > Postgraduate 22 12%
Student > Ph. D. Student 19 10%
Researcher 19 10%
Other 42 23%
Unknown 33 18%
Readers by discipline Count As %
Medicine and Dentistry 91 49%
Nursing and Health Professions 13 7%
Social Sciences 7 4%
Psychology 6 3%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Other 19 10%
Unknown 44 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2021.
All research outputs
#3,860,720
of 19,088,857 outputs
Outputs from Cochrane database of systematic reviews
#6,472
of 11,929 outputs
Outputs of similar age
#61,165
of 305,751 outputs
Outputs of similar age from Cochrane database of systematic reviews
#140
of 235 outputs
Altmetric has tracked 19,088,857 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,929 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.0. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,751 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.